Skip to main content
Publications
Phiri K, Hallas J, Linder M, Margulis A, Suehs B, Arana A, Bahmanyar S, Hoffman V, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S, Kristiansen NS, Appenteng K, de Vogel S, Seeger J. A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder. Curr Med Res Opin. 2021 May;37(5):867-77. doi: 10.1080/03007995.2021.1891035
McIntyre RS, Patel MD, Masand PS, Harrington A, Gillard P, McElroy SL, Sullivan K, Montano CB, Brown TM, Nelson L, Jain R. The Rapid Mood Screener (RMS): a novel and pragmatic screener for bipolar I disorder. Curr Med Res Opin. 2021 Jan;37(1):135-44. doi: 10.1080/03007995.2020.1860358
Pariser DM, Simpson EL, Gadkari A, Bieber T, Margolis DJ, Brown M, Nelson L, Mahajan P, Reaney M, Guillemin I, Mallya UG, Eckert L. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Curr Med Res Opin. 2020 Mar;36(3):367-76. doi: 10.1080/03007995.2019.1699516
Goyal RK, Cuyun Carter G, Nagar SP, Smyth EN, Price GL, Huang YJ, Li L, Davis KL, Kaye JA. Treatment patterns, survival, and economic outcomes in Medicare-enrolled, older patients with HR+/HER2– metastatic breast cancer. Curr Med Res Opin. 2019 Oct;35(10):1699-710. doi: 10.1080/03007995.2019.1615422
Govindan R, Senan S, Dickgreber N, Provencio M, Wu YL, Syrigos K, Parente B, Wilson M, Ziemiecki R, Chouaki N, Hossain A, San Antonio B, Winfree K, Vokes EE. Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer. Curr Med Res Opin. 2019 Oct;35(10):1761-7. doi: 10.1080/03007995.2019.1623185
Garratt C, Weatherall M, Pohjanjousi P, Aantao R, Conti G, Lewis M, Moore N, Perez-Gutthann S. A multinational, drug utilisation study to investigate the use of dexmedetomidine (DEXDOR®) in clinical practice in the EU. Poster presented at the 2015 ESICM's 28th Annual Congress; October 3, 2015. Berlin, Germany. [abstract] Intensive Care Med Exp. 2015 Oct 1; 3(Suppl 1):A322. Previously presented at the 31st ICPE International Conference on Pharmacoepidemiology and Therapeutic Risk Management. doi: 10.1186/2197-425X-3-S1-A322
Campone M, Beck JT, Gnant M, Neven P, Pritchard KI, Bachelot T, Provencher L, Rugo HS, Piccart M, Hortobagyi GN, Nunzi M, Heng DYC, Baselga J, Komorowski A, Noguchi S, Horiguchi J, Bennett L, Ziemiecki RM, Zhang J, Cahana A, Taran T, Sahmoud T, Burris HA. Health-related quality of life and disease symptoms in postmenopausal women with HR+, HER2- advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy. Curr Med Res Opin. 2013 Sep 4;29(11):1463-73.